BioNTech Wins UBS Backing and a Gilead Pact While Its Pipeline Delivers a Mixed Verdict

UBS analyst David Dai reaffirmed his buy rating on BioNTech yesterday, keeping a 135 US-dollar price target in place. The call rests on a single set of impressive congress data for a combination therapy in lung cancer — not on a clean sweep across the German biotech's oncology portfolio. That distinction matters, because the same pipeline is simultaneously producing results that range from moderate to disappointing.

The shares slipped 1.3% on the day of the UBS note, and the broader picture is similarly subdued: at 77.80 euros the stock sits 26% below its 52-week high of 105.80 euros, a decline of 1.1% in the latest session. Neither the analyst endorsement nor a fresh partnership announcement has been enough to shift that trajectory.

A combination that impressed — and what it does not prove

Dai described congress data for a pairing of a bispecific antibody with an antibody-drug conjugate as impressive, pointing to high efficacy in solid tumours and what he regards as a flawless safety profile. His endorsement is a clinical judgement about one specific regimen. It is not a regulatory decision, and it says nothing about whether other combinations will replicate those results. Safety findings, in particular, have to stay tied to the treatment schedule actually studied.

Separate data from ROSETTA Lung-107, run with Bristol Myers Squibb, offer further context for the combination approach — though with a different regimen. The trial tested Pumitamig plus docetaxel in previously treated metastatic non-small cell lung cancer, in patients who had already received both immunotherapy and chemotherapy. Among 30 evaluable patients, the confirmed objective response rate came in at 36.7% and the disease control rate at 90.0%. Pumitamig remains investigational and is not approved.

Gilead deal targets triple-negative breast cancer

On Thursday BioNTech added a strategic piece to that puzzle, signing a collaboration and supply agreement with Gilead Sciences. The plan is to combine BioNTech's own Pumitamig with Gilead's antibody-drug conjugate sacituzumab govitecan in the first-line treatment of patients with locally advanced or metastatic, PD-L1-low or -negative triple-negative breast cancer. The corresponding amendment to a Phase 3 study is still subject to regulatory approvals.

The arrangement fits a broader shift in how the Mainz-based company operates. Rather than going it alone, it is leaning increasingly on alliances with large pharmaceutical players — a model that buys access to combination studies but leaves the ultimate verdict to the biology inside the tumour.

AHEAD-MERIT falls short as DYNASTY-Breast02 clears its bar

The Gilead news lands in a stretch where BioNTech is releasing study data at a near-weekly clip. Roughly two weeks ago, the Phase 2/3 AHEAD-MERIT trial of BNT113 plus pembrolizumab failed to show a significant progression-free survival advantage over pembrolizumab monotherapy in HPV16-positive head and neck cancer. The study continues in order to capture overall survival.

Elsewhere the news has been better, if qualified. In the Phase 3 DYNASTY-Breast02 trial with partner DualityBio, trastuzumab pamirtecan hit its primary endpoint, delivering a statistically significant but moderate improvement in progression-free survival versus chemotherapy in HR-positive, HER2-low metastatic breast cancer, with interim overall survival data still immature. The companies characterised the benefit as limited. Interstitial lung disease also occurred more frequently than in earlier studies, including a small number of severe or fatal cases, and the partners are discussing next steps.

Sixteen abstracts, one market that wants survival data

BioNTech has said it will present 16 oncology abstracts at the European cancer congress ESMO in Madrid, an effort to make progress in the late-stage pipeline visible. The sheer volume of data documents how much clinical activity is under way.

Investors, though, are no longer extending blind faith to biotech narratives. What the market wants is unambiguous, clinically meaningful survival benefit — not statistical signals at surrogate endpoints. The gap between a reached endpoint and a genuinely useful drug is precisely where BioNTech's shares currently sit.

November 3 is the next hard datapoint

Clarity on the financial position and operating progress should arrive on 3 November 2026, when BioNTech reports third-quarter 2026 results and provides a business update. Until then, the investment case rests on a valuation that reflects a period of reorientation: the enormous cash reserves built up during the pandemic years are being funnelled into late-stage clinical work, without any reliable way yet to model the revenue streams that might follow.

For holders, the lesson of the past few weeks is that a convincing combination does not validate an entire cancer portfolio. Each asset and each indication has to be judged on its own efficacy and safety record — which is exactly why a buy recommendation and cautiously received individual results can sit side by side at BioNTech without contradiction.